Company news
Zentalis Pharmaceuticals, Inc. news in 2025
Zentalis Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
November 10, 2025
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 3, 2025
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
November 3, 2025
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 13, 2025
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
August 26, 2025
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
August 6, 2025
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 1, 2025
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
May 14, 2025
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
April 28, 2025
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
April 23, 2025
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
March 26, 2025
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
March 25, 2025
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
March 15, 2025
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
March 3, 2025
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
January 27, 2025
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
January 8, 2025
Decks in 2025
- Investor Presentation (November 2025)
Investor deck · 37 slides · Nov 10, 2025
- Investor Presentation (August 2025)
Investor deck · 37 slides · Aug 6, 2025
- SGO Annual Meeting on Women's Cancer 2025
Conference · 14 slides · Mar 17, 2025
- Corporate Update (January 2025)
Corporate update · 45 slides · Jan 29, 2025